Is BCMA The Answer to Treating Multiple Myeloma?
Newsletter Signup | Join Community | Cancer Types
FDA Approves first CAR T-cell therapy in patients with multiple myeloma.
Darzalex is effective myeloma treatment in several settings - most recently for transplant ineligible patients.
Ask The Expert about stem cell transplant and CAR T cell therapy during the COVID pandemic.
Xpovio treatment of Multiple Myeloma receives FDA approval - combination appears superior to Vd with less neuropathy.
Talquetamab is a CPRC5DxCD3 Bispecific Antibody being developed for the treatment of myeloma - early results promising.
Pfizer PF-06863135, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody.
BCMAxCD3 Bispecific Teclistamab show preliminary effectiveness in patients with advanced Multiple Myeloma
Clinical results for REGN 5458 Bispecific Antibody appear promising for treatment of advanced myeloma-2020 ASH Update
Has anyone elected to receive triple drug therapy and delay their ASCT? Seems like there is…
New Antibody that targets CD74 on myeloma cells gets nod from FDA to proceed.…
UK doctors identify a new target for treating Multiple Myeloma: http://www.imperial.ac…